


View Article Online View Journal

RSC Advances

This article can be cited before page numbers have been issued, to do this please use: A. K. Chakraborti, B. Tanwar, P. Purohit, B. Naga Raju, D. Kumar and D. N. Kommi, *RSC Adv.*, 2015, DOI:



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

ARTICLE TYPE

An "all-water" strategy for regiocontrolled synthesis of 2-aryl quinoxalines

Babita Tanwar, Priyank Purohit, Banothu Naga Raju, Dinesh Kumar, Damodara N. Kommi and Asit K. Chakraborti *^a

s Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x


A new synthetic strategy of tandem *N*-aroylmethylation–nitro reduction–cyclocondensation has been developed for the first and generalized regioselective synthesis of 2-aryl quinoxalines adopting "all water chemistry." Water plays the critical role through hydrogen bond driven 'synergistic electrophile-

¹⁰ nucleophile dual activation' for chemoselective *N*-aroylmethylation of *o*-nitroanilines, that underlines the origin of the regioselectivity, as the use of organic solvents proved to be ineffective. Water also provides beneficial effects during the nitro reduction and the penultimate cyclocondensation steps.

Introduction

Published on 09 January 2015. Downloaded by UNIVERSITY OF OTAGO on 12/01/2015 04:43:49.


Quinoxalines exhibit a wide range of biological activities,¹ ¹⁵ represent the essential pharmacophoric feature of various drugs (Scheme 1)² and find versatile applications in material sciences.³



Scheme 1. A few quinoxaline-based drugs.

These have triggered interest to develop synthetic methodologies 20 of quinoxalines that involve the Lewis/Brönsted acid or Lewis base promoted reaction of o-phenylenediamines (commercially available or prepared in situ by reduction of the corresponding onitroanilines or 1,2-dinitrobenzenes) with various coupling partners such as 1,2-diketones (preformed or prepared in situ 25 from acetylene derivatives), 1,2-ketomonoximes, αhydroxyketones/α-haloketones, 1.2-diols, α-methyleno aldehydes/ketones, substituted epoxides, substituted nitroolefins.⁴ However, regiocontrolled construction of the quinoxaline

- scaffold from unsymmetrical substrates (reacting/coupling ³⁰ partners) remains elusive. Some of the reported procedures⁵ form regioisomeric mixtures while in all others⁴ the regioselectivity issue remained unaddressed/suppressed. It was realized that the reported procedures^{4,5} involve simultaneous condensation of 1,2bisnucleophiles with 1,2-bis-electrophilic coupling partners
- ³⁵ (Scheme 2) and hence are ought to be associated with the regioselectivity problem.



Scheme 2. Regioselectivity in the synthesis of quinoxalines.

⁴⁰ This presses the necessity for a new synthetic design for regioselective construction of the quinoxaline moiety. Herein we present a new strategy of "all-water" tandem *N*-aroylmethylationreduction-cyclocondensation process for one-pot synthesis of 2aryl quinoxalines in regiodefined manner (Scheme 3).

	$\left(\begin{array}{c} 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 \\ 1 $	$\xrightarrow{\text{ater}} \overset{\text{NH}_2}{\underset{\text{R}_4}{\longrightarrow}} \overset{\text{NH}_2}{\underset{\text{H}_4}{\longrightarrow}} Ar$	$\xrightarrow{In/HCl}_{Water} \xrightarrow{R_3} \xrightarrow{NO_2}_{H} \xrightarrow{Ar}$	$\xrightarrow{\text{water}} \bigcup_{R_1}^{NO_2} NO_2$	O Ar Br 2
45	5	4 '' 0	3 1 0	1	2

Scheme 3. "All-water" *N*-aroylmethylation-reduction-cyclocondensation strategy for regiocontrolled synthesis of quinoxalines.

Results and Discussion

(entries 5-9, Table 1).

- As the *N*-aroylmethylation is the critical step, to test the ⁵⁰ feasibility of the metal and base-free C-N bond formation, in a model study *o*-nitroaniline (**1a**) was treated with α bromoacetophenone (**2a**) (Scheme 3, R = H) in various solvents to form 2-[(2-nitrophenyl)amino]-1-phenylethanone (**3a**) (Table 1). The 2-[(2-nitrophenyl)amino]-1-phenylethanone (**3a**) was ⁵⁵ obtained in excellent yields (91-92%) in water. The comparable results in tap, pure, and ultra pure water (entries 2-4, Table 1) indicate that the *N*-benzoylmethylation is not influenced by any dissolved metallic/organic impurities. The specific assistance of water in promoting the metal/base free *N*-benzoylmethylation is ⁶⁰ revealed by the fact that **3a** was formed in poor yield under neat condition (entry 1, Table 1) and in hydrocarbon, halogenated hydrocarbon, ethereal, and aprotic polar solvents (entries 10–20, Table 1). Alcohols (protic polar solvents) gave moderate yields
- ⁶⁵ **Table 1.** Influence of the reaction medium for a metal/catalyst and base-free selective *N*-monobenzoylmethylation of **1a** with **2a**.

18

19

20

21

23

24

65 22

NO₂

NO₂

		+			[]	í ì
		NH ₂ Br	110 °C/Refl	ux, 5 h	N H	\sim
	1a	2a Ö			3a	Ö
	Entry	Solvent	Temp	$\alpha^{\rm b}$	β^{b}	Yield
			(°C)			(%) ^c
	1	None	110			7
5	2	Tap water	Reflux	1.17	0.18	92
	3	Pure water ^d	Reflux	1.17	0.18	91
	4	Ultra pure water ^e	Reflux	1.17	0.18	92
	5	MeOH	Reflux	0.93	0.62	59
	6	EtOH	Reflux	0.83	0.77	65
10	7	ⁱ PrOH	Reflux	0.76	0.95	68
	8	^t BuOH	Reflux	0.68	1.01	74
	9	TFE	Reflux	1.51	0.00	50
	10	Toluene	Reflux	0.00	0.11	31
	11	Hexane	Reflux	0.00	0.00	trace
15	12	DCE	Reflux	0.00	0.00	35
	13	1,4-Dioxane	Reflux	0.00	0.37	55
	14	THF	Reflux	0.00	0.55	21
	15	Acetone	Reflux	0.08	0.48	13
	16	MeNO ₂	Reflux	0.22	0.00	33
20	17	DMF	110	0.00	0.69	36
	18	DMA	110	0.00	0.76	nil
	19	Formamide	110	0.71	0.00	23
	20	MeCN	Reflux	0.19	0.31	trace

solvent (5 ml.)

^a**1a** (1 mmol) was treated with **2a** (1.5 mmol, 1.5 equiv) in the appropriate solvent (5 mL), except for entry 1, under heating at 110°C (oil bath) for 5 h. ^bThe α and β values represent the hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA) property of the solvent as provided under Ref 13. ^cIsolated yield. ^dPure water was obtained by purification of normal/tap water through reverse osmosis and ionic/organic removal and 30 has the resistivity of 15 MΩ at 25 °C. ^cUltrapure water was obtained by further subjecting pure water to UV treatment (185/254 nm), deionization and ultra membrane filtration (0.01 µm under pressure up to 145 psi (10 bar) and has the resistivity of 18.2 MΩ at 25 °C.

Further studies on the variation of different reaction parameters, ³⁵ such as the molar equivalents of **2a**, amount of water, temperature, and time revealed the use of 1.0 molar equivalent of **2a** in water (2 mL/mmol of **1a**) at 110 °C (oil bath) for 3 h to be the optimal condition (entry 19, Table 2).

Table 2. *N*-Benzoylmethylation of *o*-nitroaniline (1a) under different $_{40}$ condition.^a

NO ₂ + NH ₂ + Br			water Temp	•	
1a		2a ^Ö		3a	0
Entry	Water	Temp	Time	Equiv of 2a ^b	Yield
	(mL)	(°C)	(h)		(%) ^c
1	5	110	5	1.0	92
45 2	5	110	5	1.1	92
3	5 5	110	5	1.2	92
4	5	110	5	1.3	93
5	5 5	110	5	1.4	92
6	5	110	5	1.5	92
50 7	0.5	110	5	1.0	68
8	1	110	5	1.0	79
9	2	110	5	1.0	92
10	3	110	5	1.0	92
11	4	110	5	1.0	92
55 12	2	rt	5	1.0	0
13	2	60	5	1.0	traces
14	2	80	5 5	1.0	41
15	2	110	5	1.0	92

^a**1a** (1 mmol) was treated with **2a** under different reaction condition in the water as a reaction medium. ^bmolar equiv with respect to **1a**. ^cIsolated ⁷⁰ yield of **3a**.


The synthetic potential of the water-assisted *N*-aroylmethylation of *o*-nitroanilines is demonstrated by the reaction of a few substituted *o*-nitroanilines **1** with substituted α -bromoacetophenones **2** to form **3** (Table 3).

75 **Table 3.** The base/catalyst-free *N*-aroylmethylation of different *o*nitroanilines (1) with different α -bromoacetophenones (2) in water to form **3**.^a

	R ¹ R ²	NO2 NH2	+ Br		₹ ³ water 110 °C	$\begin{array}{c} R^1 \\ R^2 \\ R^2 \\ 3 \end{array} \xrightarrow[]{NO_2} \\ NO_2 \\ N \\ H \\ O \\ O$
	Entry	\mathbb{R}^1	\mathbb{R}^2	R^3	Time (h)	Yield (%) ^b
80	1	Н	Н	Н	3	92
	2	Н	Н	Cl	3	91
	3	Cl	Н	Η	4	89
	4	Н	Cl	Η	4	90
	5	CH ₃	Н	Н	3	92
85	6	CH_3	Н	OMe	3	90

^a**1** (1 mmol) was treated with **2** (1 mmol, 1 equiv) in water (2 mL) at 110 $^{\circ}$ C (oil bath) for stipulated time period. ^bIsolated yield of **3**.

The reported method for the preparation of N-phenacyl-onitroanilines involve the use of base in DMF for 48 h.⁶ Anilines ⁹⁰ are known to react with α -halogenated ketones to form indoles.⁷ Thus, the results of table 2 exemplify an excellent metal and base-free C-N bond formation protocol for chemoselective synthesis N-phenacyl-o-nitroanilines. The role of water can be visualized by its ability to form hydrogen bond (HB) with the 95 NH₂ hydrogen of **1** (nucleophilic activation). The second molecule of the water dimer⁸ in turn forms HB with the Br atom of 2 (electrophilic activation) and brings the bromomethylene carbon in close proximity to the NH₂ nitrogen of 1 in the Hbonded species (Scheme 4). Further, the carbonyl oxygen of 2 100 also participates in HB formation with another water dimer in which the second water molecule forms HB with the other NH₂ hydrogen in 1. The array/network of HBs gives stability⁹ to the H-bonded cluster (Scheme 4) and facilitates 'ambiphiphilic nucleophilic-electrophilic dual activation.'10



Scheme 4. The envisaged role of water in promoting *N*-aroylmethylation of 1 with 2 to form 3.

The hydrogen-bond assisted/mediated formation of non-covalent

NO

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

adduct of the reactants and the promoter has been invoked in various organo-catalytic chemical reactions/synthesis.¹¹

The physico-chemical parameters (acceptor/donor number etc.) of the solvent often play key role in organic reactions,¹² and the HB involving the reactant and the solvent has significant influence.¹³ Therefore, the role of the reaction medium for *N*aroylmethylation can be visualised through the formation of the HB adducts (Scheme 4) due to the hydrogen bond donor (HBD) (α scale) and hydrogen bond acceptor (HBA) (β scale) properties

¹⁰ of the solvent.¹⁴ Although, the HBD property (α value) is expected to play the predominant role in activating the electrophile (**2a**) the HBA ability (β value) is also important as it determines the ability of the solvent to activate the nucleophile (amine nitrogen of **1a**). Therefore, TFE gave inferior results due ¹⁵ to its poor β value (entry 9, Table 1).

The reduction of nitro group of **3a** would form the intermediate **4a** which on cyclocondensation would form the 2-phenyl quinoxaline **5a** (Scheme 3, R = H). However, treatment of **3a** with In (2.5 equiv) and 12N HCl (5 equiv)¹⁵ in water (2 mL)

²⁰ afforded **5a** in 24% yield at 110 °C (oil bath) after 3 h (Table 4). Further studies on standardization of the reaction conditions revealed that the best result (90% yield) is obtained in using 5 equiv of 2N HCl (entry 3, Table 4). Organic solvents gave inferior results highlighting the beneficial effect of water on the ²⁵ reduction due to enhanced solvation of the In³⁺ cation in water

making the electron transfer more efficient.¹⁶ **Table 4.** The effect of solvent and the amount of aq. HCl and In metal on the cascade reduction-cyclocondensation step.^a

	NO ₂		5 equiv)/aq HCl		N
_	н " 3а ^О			:	5a
30 Entry	Solvent	In metal	aq HCl	Equiv ^b	Yield
		(mmol)	(mL)		(%) ^{c,d}
1	water	2.5	12N (0.4 mL)	5	24
2	water	2.5	6N (0.8 mL)	5	59
3	water	2.5	2N (2.5 mL)	5	90 ^{e,f}
35 4	water	2.5	2N (2 mL)	4	67
5	water	2.5	2N (1.5 mL)	3	42
6	water	2.5	2N (1 mL)	2	21
7	water	2.0	2N (2.5 mL)	5	64
8	water	1.5	2N (2.5 mL)	5	44
40 9	EtOH	2.5	12N (0.4 mL)	5	trace
10	Toluene	2.5	12N (0.4 mL)	5	42
11	Toluene	2.5	2N (2.5 mL)	5	27
12	Dioxane	2.5	12N (0.4 mL)	5	nil
13	DCE	2.5	12N (0.4 mL)	5	nil
45 14	MeCN	2.5	12N (0.4 mL)	5	nil
15	DCE	2.5	12N (0.4 mL)	5	nil
16	THF	2.5	12N (0.4 mL)	5	nil
17	DMF	2.5	12N (0.4 mL)	5	nil
18	none	2.5	2N (2.5 mL)	5	14

ARTICLE TYPE

⁵⁰ ^aTo the mixture of **3a** (1 mmol) in water (2 mL, entries 1-6) or the specified organic solvent (4.1 mL, entries 7-15) was added In metal (1.5-2.5 equiv as indicated against each entry) and the indicated amount (in ML) of aq HCl at 110 °C (oil bath) and the mixture was stirred magnetically for 3 h. ^bMolar equiv of HCl. ^cIsolated yield of **5a**. ^dThe ⁵⁵ unreacted **3a** remained unchanged and could be recovered wherever **5a** was formed in poor yields. ^cOnly trace amount of **5a** was obtained in 63% yield in performing the reaction at 80 °C.

To find out whether indium metal can be replaced by other less costly metals such as Fe, Zn, Mg, Sn, or $SnCl_2 \cdot 2H_2O$, **3a** was treated with different metals/reducing agent (2.5 equiv) in aq HCl (2N 2.5 mL, 5 equiv) (Table 5).

 Table 5. The effect of different metals/reducing agent on the

 65 cascade reduction-cycloconden sation step.^a


	NO N H 3a		metal (2.5 equiv) water (2 mL) 2.5 mL 2N aq HCI (5 110 °C, 3 h	equiv) N
	Entry	Metal	Isol	ated Yield of 5a (%)
	1	In	90	
	2	Fe	61	
70	3	Zn	trac	e ^b
	4	Mg	trac	e ^b
	5	Al	25 ^b	
	6	Sn	64	
	7	SnCl ₂ ·	2H ₂ O 65	

⁷⁵ ^aTo the mixture of **3a** (1 mmol) in water (2 mL) was added metal or the indicated reducing agent (2.5 equiv) and aq HCl (2N, 2.5 mL; 5 equiv) at 110 °C (oil bath) and the mixture was stirred magnetically for 3 h. ^bThe unreacted **3a** remained unchanged and could be recovered.

Thus, the use of indium metal provided the best results. The product isolation was found to be tedious in case of aluminium due to gel formation in the reaction mixture. The use of Sn metal or its popularly used salt $SnCl_2 \cdot 2H_2O$ were also less effective.¹⁷

To determine whether indium metal would offer similar beneficial effect compared to Fe, Zn, Mg, Sn, or SnCl₂·2H₂O for ⁸⁵ the one pot tandem *N*-aroylmethylation-reduction-condensation, **1a** was sequentially treated with **2a** in water followed by different metals/reducing agent (2.5 equiv) in aq HCl (2N 2.5 mL, 5 equiv) to form **5a** (Table 6). The best result was obtained in using indium metal. Herein also poor yields were obtained with Sn ⁹⁰ metal and SnCl₂·2H₂O.¹⁷

Table 6. The effect of different metals/reducing agent on the tandem *N*-aroylmethylation- reduction-cyclocondensation during the reaction of 1a with 2a to form 5a.^a




RSC Advances Accepted Manuscrip

Published on 09 January 2015. Downloaded by UNIVERSITY OF OTAGO on 12/01/2015 04:43:49.


4	Mg	trace ^b
5	Al	15 ^b
6	Sn	63
7	SnCl ₂ ·2H ₂ O	57

Published on 09 January 2015. Downloaded by UNIVERSITY OF OTAGO on 12/01/2015 04:43:49.

- ⁵ ^a1a (1 mmol) was treated with 2a in water (2 mL) at 110 °C (oil bath) for 3 h followed by addition of the metal/reducing agent (2.5 equiv) and aq HCl (2N, 2.5 mL; 5 equiv) at 110 °C (oil bath) and the mixture was stirred magnetically for further 3 h. ^bThe unreacted 1a and 2a remained unchanged.
- ¹⁰ The poor yields of **5a** obtained in organic solvents (Table 4) during the treatment of **3a** with In/HCl raised the query as to whether the use of aqueous medium exerts beneficial effect only for the nitro reduction or its beneficial effect extends for the subsequent cyclocondensation step as well. To distinguish any
 ¹⁵ role of water in the cyclocondensation of **4a** to **5a**, it was felt necessary to treat the preformed **4a** in water as well as in organic solvents. However **4a** could not be isolated by the In/HCl reduction of **3a**, although the MS spectra of the crude reaction mixture exhibited ion peak corresponding to **4a**. Attempts such as
 ²⁰ (i) Pd/C mediated hydrogenation of **3a** (Scheme 5), and (ii) reaction of *o*-phenylenediamine (**6**) with **2a** (Scheme 6) were unsuccessful and resulted in the formation of **5a** in 35 and 60%



25 Scheme 5. Pd-Catalysed hyrogenation of 2-[(2-nitrophenyl)amino]-1phenylethanone (3a).



Scheme 6. Reaction of *o*-phenylenediaimine (6) with α -bromoacetophenone (2a).


³⁰ Thus, it was planned to prepare **8a** [pro-**4a**] which would generate **4a** in-situ through *N*-Boc deprotection under acid/metal-free condition (Scheme 7). Although a few methods¹⁸ were reported for mono-*N*-Boc formation of **6**, repetition of some of these led to the mixture of the mono- and di-*N*-Boc derivatives of ³⁵ **6** (Table 7).

Table 7. Preparation of *tert*-butyl (2-aminophenyl)carbamate (7a).^a

(-) -							
Ĺ		+ (Boc) ₂ O	solvent Temp			+ +	74	H N-Boc N-Boc
-	-	O Catalyst	Solvent		Temp	Time	7b Yie	ld (%) ^b
40	(equiv)	(mol%)	(amt)		(°C)	(h)	7a	~ ~
1	1.2	Gu·HCl ^c (15)EtOH (1 mL)	35-40	3	52	28
2	1	$LiClO_4(20)$	DCM (2 mL)	30-40	5	42	23
3	1	none	DCM (1 mL)	0	2	64	21
4	1	Iodine (10)	neat	, 	35-40	4	35	35
45 5	1	none	EtOH (4 mL)	30	0.5	71	22


^aTreatment of **6** (1 mmol) under different reaction condition in different solvents at specified temperature for specified time. ^bIsolated yield.^cGu·HCl stands for guanidinium hydrochloride.

The mono-*N*-Boc **7a** was obtained in 71% yield following ⁵⁰ modification of literature report^{18e} and was treated with **2a** in



Scheme 7. Synthesis of 8a

The acid/metal-free *N*-Boc deprotection is reported to take place ⁵⁵ in water¹⁹ and trifluoroethanol (TFE)²⁰ under heating. The treatment of **8a** in water 110 °C (oil bath) gave **5a** in 82% yield after 2 h (Scheme 8). This indicated that the cyclocondensation of the in situ formed **4a** to **5a** is promoted by water. However, **5a** was formed in 15% yield by the treatment of **8a** in TFE under ⁶⁰ reflux for 24 h. No significant amount of **5a** was obtained by the treatment of **8a** in TFE under reflux for 5 h. The treatment of **8a** in water (in place of TFE) under similar condition (80 °C for 5 h) afforded **5a** in 71% yield. Thus, water is the best solvent for the cyclocondensation step due its favourable α and β values that ⁶⁵ render a better 'dual activation' ability of water compared to



Scheme 8. Acid/metal-free cyclocondensation of 7a to form 5a

The generality of the new strategy of 'all water' one-pot tandem ⁷⁰ *N*-aryolmethylation-reduction-condensation for synthesis of 2aryl quinoxalines is demonstrated by sequential treatment of various *o*-nitroanilines with different α -bromoacetophenones in water under heating followed by treatment with In/HCl (2N) (Table 8).

75	Table 8.	'All water'	cascade synthesis of 2-aryl quinoxalines. ^a	

	R^1 R^2 1	NO ₂ NH ₂ + E			i) water, 11() In/HCl (2N)		N N 5
	Entry	\mathbf{R}^1	\mathbb{R}^2	R ³	R^4	Time (h) ^b	Yield (%) ^c
	1	Н	Н	Н	Н	5	86
	2	Н	Н	Н	OMe	5	83
80	3	Н	Н	OMe	Н	5 5 5	84
	4	Н	Н	Н	Cl	5	82
	5	Н	Н	Н	Br	5	84
	6	Cl	Н	Н	Н	6	81
	7	Cl	Н	Н	OMe	6	80
85	8	Cl	Н	Н	Cl	6	82
	9	Cl	Н	Н	Br	6	80
	10	Н	Cl	Н	Н	6	83
	11	Н	Cl	Н	OMe	6	81
	12	Н	Cl	Н	Cl	6	82
90	13	Н	Cl	Н	Br	6	83
	14	Me	Н	Н	OMe	5	80
	15	Me	Н	Н	Br	5	80
	16	OMe	Н	Н	Н	5	82

^aI (1 mmol) was treated with 2 (1 mmol, 1 equiv) in water (2 mL) at 110
⁹⁵ °C (oil bath) for 3 h followed by addition of In (2.5 mmol, 2.5 equiv), 2N HCl (2.5 mL, 5 mmol, 5 equiv) and allowed to proceed for remaining time. ^bTotal time for the one-pot reaction.^c Isolated yield of 5.

Condensation of *o*-phenylenediamine with phenacyl bromide has been reported in water as well as organic solvents in the presence

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

of organic/inorganic catalysts to form 2-phenylqunoxalines.^{4a,d-j,5c} However, a catalyst-free protocol in water that would reflect the distinct influence of water in the *N*-aroylmethylation and subsequent cyclo-condensation step is lacking. Thus, to evaluate ⁵ any distinct advantage of water over organic solvents **6** was treated with **2a** in various solvents in the absence of any added base/acid catalyst at 110 °C (oil bath) (Table 9).

Table 9. Reaction of 6 with 2a in various solvents under catalyst-free condition.^a

10	6	NH ₂ O	solvent 110 °C or reflu 3 - 4 h	× N N 5a
	Entry	Solvent	Temp (°C)	Yield (%) ^b
	1	Water	80	62
	2	Water	Reflux	79,71°,74 ^d
	3	EtOH	Reflux	65
15	4	Toluene	Reflux	40
	5	1,4-Dioxane	Reflux	61
	6	THF	Reflux	47
	7	DMF	110	52
	8	MeCN	Reflux	45
20	9	TFE	Reflux	40

^a**6** (1 mmol) was treated with **2a** in the specific solvent (2 mL) at 80/110 °C (oil bath temperature) for 4 h (unless specified). ^bIsolated yield of **5a**. ^cThe yield of **5a** in performing the reaction for 3 h. ^dThe yield of **5a** in performing the reaction for 3 h in the presence of K₂CO₃ (1 equiv).

- ²⁵ The best yield obtained in water clearly reflect the distinct advantage of water as the reaction medium for the tandem *N*aroylmethylation-cyclocondensation. Comparable yield (74%) obtained in performing the reaction in water in the presence of K₂CO₃ (1 equiv) (Table 9, entry 2, footnote d) rules out the ³⁰ possibility of any essential role of the liberated HBr (during the
- initial *N*-aroylmethylation step) for the final cyclocondensation. The significant role of the solvent (Table 9) in the final cyclocondensation step can be demonstrated by the best results are obtained in water that acts both as good hydrogen bond donor
- ³⁵ and hydrogen bond acceptor with the second best results obtained in EtOH. The lesser yield obtained in TFE compared to that in water and EtOH is the clear reflection of the inferior hydrogen bond acceptor ability of TFE. The use of 1,4-dioxane afforded the next best result due to its appreciable hydrogen bond acceptor
- ⁴⁰ ability (to activate the amino group of the intermediately formed **4a**). The better result in 1,4-dioxane compared to that of THF could be due to the chelation effect of the two oxygen atoms in the former to form the HB with the NH₂ group more effectively. The inferior yields in DMF, MeCN and toluene are also reflection of the unforumental budgeout a band dougeneous reflection
- ⁴⁵ of the unfavourable hydrogen bond donor/acceptor ability of these solvents.

Although the quinoxaline formation by a direct condensation of **6** with **2a** becomes feasible in water under catalyst-free condition, the reaction of unsymmetrical *o*-phenylenediamine with phenacyl

ARTICLE TYPE

50 bromide is expected to form regioisomeric quinoxalines as has been observed in one of these reports.^{5c} However, the regioselectivity issue remained unaddressed/suppressed in the other reported methodologies.4a,d-j To throw light on this regioselectivity issue and establish the distinctiveness of the "all 55 water" strategy of the N-aroylmethylation-nitro reductioncyclocondensation cascade for regioselective synthesis of 2-aryl quinoxalines, the condensation of 4-chloro-1,2-phenylenediamine 9 with phenacyl bromide was performed in water as well as in organic solvents under the reported reaction conditions^{4a,d-j,5c} 60 (Table 10). In all of these cases the isolated product on being subjected to ¹H NMR analyses revealed to be a mixture of the regioisomeric products. In each case, the pure regioisomers were isolated through flash column chromatography and were identified as A and B based on the spectral data of authentic 65 compounds (products of entries 6 and 10, respectively, of Table 8) and on comparison with literature reports.^{5i,1} On the other hand, the reaction of 4-chloro-2-nitroaniline with phenacyl bromide N-aroylmethylation-reductionfollowing the tandem cyclocondensation strategy resulted in exclusive formation of one 70 of the regioisomeric quinoxalines without any concomitant formation of the other regioisomer (entry 10, Table 8). This clearly demonstrates the distinct advantage of this new synthetic strategy. The unambiguous route of construction of the quinoxaline scaffold under the present method forms the basis of 75 regioselectivity control.

Table 10. Reaction of I with 2a under the reported reaction conditions.^a

CINH2 NH2	Br solvent	CI	N N Ha) +	N N Hb
9	0 2a	4	4		В
Entry Catalyst ^b	Solvent	Temp	Time	(A : B) ^c	yield (%) ^d
		(0.00)	<i>a</i> .		

	(mol%)		(°C)	(h)		A	B	
80 1	Pyridine (10)	THF	rt	2	20:80	25	45	
2		PEG-400	80	8	83:17	65	15	
3	β-CD (1 equiv)	Water	70	3	79:21	63	21	
4	TMSCl (1 equiv)	Water	70	8	86:14	51	12	
5	CTAB (20)	Water	10	8	34:65	25	62	
85 6	HClO ₄ -SiO ₂	MeCN	rt	1	22:77	15	63	
	(50 mg)							
7	TBAB (20)	Water	rt-70	4.5	72:28	51	18	
	$+ K_2 CO_3 (2 equiv)$							
8	DABCO (20)	THF	rt	1	32:67	12	62	
90 9		Water	110	7	58:42	33	41 ^e	

^aI (1 mmol) was treated with 2a under the various reported reaction conditions. ^bLit ref: 4a, 4e-j, and 5c for entries 1-8, respectively. ^cRegioisomeric distribution based on Ha and Hb proton integration value in the ¹H NMR of the crude reaction mixture. ^dIsolated yield after flash ⁹⁵ column chromatography. ^cData generated under the condition of the present study.

Conclusions

A new synthetic strategy of 'all water' tandem aroylmethylationnitro reduction-cyclocondensation is reported for the first and generalized regioselective synthesis of 2-aryl quinoxalines. Water plays the critical role through hydrogen bond driven 'synergistic 5 electrophile nucleophile dual activation' during the Naroylmethylation and provides the basis of quinoxaline formation in regiodefined manner. Water also exerts beneficial effect during the nitro reduction-cyclocondensation cascade and makes this synthetic strategy a true example of 'all-water chemistry.'

10 Experimental section

Published on 09 January 2015. Downloaded by UNIVERSITY OF OTAGO on 12/01/2015 04:43:49.

General remarks: The glasswares used were thoroughly washed and dried in an oven and the experiments were carried out with required precautions. Chemicals and all solvents were commercially available and used without further purification. The 15 TLC experiments were performed on silica gel GF-254 and visualized under UV at 254 nm. Evaporation of solvent was performed at reduced pressure using a rotary evaporator. Melting points were measured using a melting point apparatus and were uncorrected. The ¹H and ¹³C NMR spectra were recorded on a 20 400 MHz NMR spectrometer in CDCl₃ with residual undeuterated solvent (CHCl₃: 7.26/77.0) using Me₄Si as an internal standard. The chemical shift (δ) values are given in ppm and J values are given in Hz. The ${}^{13}C$ NMR spectra were fully decoupled and were referenced to the middle peak of the solvent 25 CDCl₃ at 77.00 ppm. Splitting pattern were designated as s, singlet; bs, broad singlet; d, doublet; dd, doublet of doublet; t, triplet; dt, doublet of triplet and m, multiplet. The mass spectra (MS) were recorded under atmospheric pressure chemical ionization (APCI) and electrospray ionization (ESI). The high

- 30 resolution mass spectra (HRMS) were recorded under electrospray ionization (ESI). The infra-red (IR) spectra were recorded in the range of 4000-600 cm⁻¹ as KBr pellets for all solid samples. Preparation of Pure water (15 MΩ-cm resistivity at 25 °C):
- 35 The pure water was prepared by subjecting the tap water for reverse osmosis and ionic/organic removal by passing through pre-packed cartridge.

Preparation of Ultrapure water (18.2 MΩ-cm resistivity at 25

- °C): The ultrapure water was prepared by subjecting the pure 40 water for UV treatment (185/254 nm UV Lamp), deionization by passing through deionization cartridge followed by ultra membrane filtration (0.01um) under pressures up to 145 psi (10 bar). Ultrapure water (UPW) is generally considered to be ≥ 18.2 M Ω -cm resistivity at 25°C, low ppt in metals, less than 50 ppt in
- 45 inorganic anions and ammonia, less than 0.2 ppb in organic anions, and below 1 ppb total organic carbon (TOC) and silica (dissolved and colloidal).

Typical procedure for selective mono-N-benzoylmethylation of o-nitroaniline (1a): The mixture of o-nitroaniline 1a (138 mg,

50 1 mmol) and α -bromacetophenone 2a (199 mg, 1 mmol, 1 equiv) in water (2 mL) was stirred magnetically at 110 °C (oil-bath). After completion of the reaction (3 h, TLC), the reaction mixture was extracted with EtOAc (3 \times 5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, and the filtrate was 55 concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg),

400 mesh size, 2.5 g), and eluted with hexane-EtOAc (95:5) to obtain analytically pure 2-((2-nitrophenyl)amino)-1-60 phenylethanone (Table 2, Entry 1) (3a) as Yellow solid (236 mg, 92 %); mp = 147-149 °C; IR (KBr) v_{max} = 3433, 2926, 2872, 1735, 1619, 1570, 1514, 1453, 1352, 1259, 1106, 951, 749 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ: 8.92 (bs, 1H), 8.25 (dd, J=1.5, 8.5Hz, 1H), 8.07-8.05 (m, 2H), 7.69-7.65 (m, 1H), 7.58-

- 65 7.48 (m, 3H), 6.84-6.82 (m, 1H), 6.76-6.72 (m, 1H), 4.80 (d, J=4.4Hz, 2H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 192.71, 143.97, 136.22, 134.44, 134.22, 132.70, 129.04, 127.89, 127.08, 115.98, 114.14, 49.42; MS (APCI) m/z: 257 (M+H)⁺. HRMS (ESI) m/z calcd for $C_{14}H_{12}N_2O_3Na^+$ [M+Na⁺], 279.0740; Found 70 279.0740.
- Typical procedure for the cascade reduction-condensation of 3a to 5a: To the mixture of 2-[(2-nitrophenyl)amino]-1phenylethanone 3a (256 mg, 1 mmol) in water (2 mL) was added In metal (287 mg, 2.5 mmol, 2.5 equiv) and 2N HCl (2.5 mL, 5 75 mmol, 5 equiv), and the mixture was stirred magnetically at 110 °C (oil-bath) for 3 h (TLC). The reaction mixture was extracted with EtOAc (3 \times 5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, and the filtrate was concentrated under rotary vacuum evaporation. The crude product was 80 adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to obtain analytically pure 5a as a pale orange solid (185 mg, 90%)^{4a} (Table 4).
- 85 Typical procedure for 'all water' one-pot tandem Naryolmethylation-reduction-condensation for synthesis of 2aryl quinoxalines. Synthesis of 5a: The mixture of onitroaniline 1a (138 mg, 1 mmol) and α -bromacetophenone 2a (199 mg, 1 mmol, 1 equiv) in water (2 mL) was stirred
- 90 magnetically at 110 °C (oil-bath) for 3 h followed by addition of In (287 mg, 2.5 mmol, 2.5 equiv), 2N HCl (2.5 mL, 5 mmol, 5 equiv) and the reaction mixture was allowed to stir till the completion of reaction (2 h, TLC). The reaction mixture was extracted with EtOAc (3×5 mL). The combined EtOAc extracts
- 95 were dried (anh Na₂SO₄), filtered, and the filtrate was concentrated under rotary vacuum evaporation. The crude product was recrystallized from EtOH to afford analytically pure 2-phenylquinoxaline (Table 8, Entry 1) (5a) as a pale orange solid (177 mg, 86 %). mp = 75-76 °C; v_{max} = 3005, 2325, 1275,
- ¹⁰⁰ 1260, 764, 750 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.26 (s, 1H), 8.15-8.05 (m, 4H), 7.72-7.65 (m, 2H), 7.52-7.45 (m, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 151.68, 143.26, 142.21, 141.53, 136.69, 130.19, 130.13, 129.57, 129.45, 129.07, 127.48; MS (ESI) m/z: $207 (M+H)^{+.4a}$

105 In an alternative purification procedure the crude product was adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to obtain analytically pure 2-phenylquinoxaline (Table 8, Entry 1) (5a) as a 110 pale orange solid (173 mg, 84 %).

In general, the purification was made by crystallization except for low melting (< 65 °C) compounds wherein the purification was made through column chromatography.

Experimental procedure for the various attempts for the 115 synthesis of 2-((2-aminophenyl)amino)-1-phenylethanone

ARTICLE TYPE

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

(4a):

Pd-Catalysed hydrogenation of 2-[(2-nitrophenyl)amino]-1phenylethanone (3a) (Scheme 5). Pd/C (5%) (10 mg) was added to the of 3a (256 mg, 1 mmol) in toluene (10 mL) and kept under 5 H₂ atmosphere at room temperature at 40 psi pressure. After 6 h, the Pd/C was removed by filtration and the filtrate was concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-10 400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to

obtain analytically pure 5a as a pale orange solid (72 mg, 35%).^{4a} Reaction of *o*-phenylenediaimine (6) with α bromoacetophenone (2a) (Scheme 6):

To the mixture of *o*-phenylenediaimine (6) (108 mg, 1 mmol) and 15 α -bromacetophenone (2a) (199 mg, 1 mmol, 1 equiv) in MeCN (2 mL) was added K₂CO₃ (276 mg, 2 mmol, 2 equiv) and stirred magnetically under reflux condition. After completion of the reaction (4 h, TLC), the reaction mixture was extracted with EtOAc (3 × 5 mL). The combined EtOAc extracts were dried

20 (anh Na₂SO₄), filtered, and the filtrate was concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to obtain analytically pure 25 **5a** as a pale orange solid (123 mg, 60%).^{4a}

Experimental procedure for the synthesis of *tert*-butyl (2-[(2oxo-2-phenylethyl) aminophenyl]carbamate (8a) (Scheme 7/Table 7):

- Step 1: Preparation of *tert*-butyl (2-aminophenyl) carbamate ³⁰ (7a). *o*-Phenyldiamine (6) (108 mg, 1 mmol) was stirred at 30 °C in absolute EtOH (2 mL), and di-tert-butyl dicarbonate (218 mg, 1.1 mmol, 1.1 equiv), dissolved in absolute EtOH (2 mL), was added dropwise to the reaction mixture. After 30 min, the solvent was evaporated to dryness, and the crude material. The crude
- ³⁵ product was adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (96:4) to obtain analytically pure *tert*-butyl (2-aminophenyl)carbamate (7a) as a white solid (147 mg, 71%); mp = 110-113 °C; IR (KBr)
- ⁴⁰ $v_{\text{max}} = 3414, 3356, 2973, 1896, 1682, 1595, 1490, 1456, 1387, 1366, 1162, 1054, 1027, 850, 749 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) <math>\delta$: 7.28-7.27 (m, 1H), 7.00 (dt, *J*=1.36, 7.6Hz, 1H), 6.81-6.75 (m, 2H), 6.35 (bs, 1H), 3.75 (bs, 2H), 1.52 (s, 9H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ : 153.91, 139.99, 126.13,
- $_{45}$ 124.77, 119.56, 117.57, 80.50, 28.35; MS (ESI) m/z: 209 $\rm (M+H)^{+}.~HRMS~(ESI)~m/z~calcd~for~C_{11}H_{16}N_2O_2Na^{+}~[M+Na^{+}], 231.1109; Found 231.1114.^{17e}$

Di*tert***-butyl 1,2-phenylenedicarbamate (7b).** white solid (65 mg, 22%); mp = 105-106 °C; IR (KBr) \boldsymbol{v}_{max} = 3307, 2978, 2931,

 $_{50}$ 1699, 1601, 1527, 1457, 1248, 1158, 1049, 1025, 749 cm $^{-1};$ $^{1}\mathrm{H}$ NMR (CDCl₃, 400MHz, TMS) δ : 7.47 (bs, 2H), 7.11 (s, 2H), 6.89 (s, 2H), 1.52 (s, 18H); $^{13}\mathrm{C}$ NMR (CDCl₃, 100MHz, TMS) δ : 153.90, 130.29, 125.31, 124.22, 80.76, 28.46; MS (ESI) m/z: 309

$(M+H)^{+}.^{17a}$

- Step 2 (Scheme 7): Synthesis of *tert*-butyl (2-[(2-oxo-2-phenylethyl)aminophenyl]carbamate (8a) from 7a. The mixture of *tert*-butyl2-aminophenylcarbamate (7a) (208 mg, 1mmol) and α-bromacetophenone (2a) (199 mg, 1 mmol, 1 equiv) in water (2 mL) was stirred magnetically at rt. After ⁶⁰ completion of the reaction (12 h, TLC), the reaction mixture was extracted with EtOAc (3 × 5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, and the filtrate was concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg),
- ⁶⁵ charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (94:6) to obtain analytically pure **8a** as a light yellow solid (189 mg, 58 %); mp = 130-132 °C; IR (KBr) $\boldsymbol{v}_{max} = 3368, 2925, 1698, 1607,$ 1498, 1449, 1356, 1248, 1166, 1048, 739 cm⁻¹; ¹H NMR (CDCl₃,
- ⁷⁰ 400MHz, TMS) δ: 8.03 (d, J=7.4Hz, 2H), 7.64 (t, J=7.36Hz, 1H),
 7.53 (t, J=7.72Hz, 2H), 7.39 (t, J=7.04Hz, 1H), 7.15-7.11 (m,
 1H), 6.81 (t, J=7.44Hz, 1H), 6.74 (d, J=7.96Hz, 1H), 6.27 (s,
 1H), 4.99 (bs, 1H), 4.61 (bs, 2H), 1.56 (s, 9H); ¹³C NMR (CDCl₃,
 100MHz, TMS) δ: 195.22, 154.16, 141.16, 134.93, 133.89,
 ⁷⁵ 128.92, 127.78, 126.58, 125.60, 124.68, 118.59, 112.93, 80.57,
- 50.75, 28.36; MS (ESI) m/z: 237 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₉H₂₂N₂O₃Na⁺ [M+Na⁺], 349.1528; Found 349.1545.
- **Experimental procedure for the synthesis of 5a from 8a** (Scheme 8): The mixture of *tert*-butyl (2-[(2-oxo-2-⁸⁰ phenylethyl)aminophenyl]carbamate (8a) (326 mg, 1 mmol) in water (3 mL) was stirred magnetically at 110 °C (oil-bath) After completion of the reaction (2 h, TLC), the reaction mixture was extracted with EtOAc (3 × 5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, and the filtrate was ⁸⁵ concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg), charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to obtain analytically pure **5a** as a pale orange solid (168 mg, ⁹⁰ 82%).^{4a}

Experimental procedure for the synthesis of 5a from 8a (Scheme 8):The mixture of *tert*-butyl (2-[(2-oxo-2phenylethyl)aminophenyl]carbamate (8a) (326 mg, 1mmol) in TFE (3 mL) was stirred magnetically at 90 °C (oil-bath). After 95 completion of the reaction (24 h, TLC), the reaction mixture was extracted with EtOAc (3×5 mL). The combined EtOAc extracts were dried (anh Na₂SO₄), filtered, and the filtrate was concentrated under rotary vacuum evaporation. The crude product was adsorbed on silica gel (230-400 mesh size, 500 mg), 100 charged on to a flash chromatography column of silica-gel (230-400 mesh size, 2.5 g), and eluted with hexane-EtOAc (99:1) to obtain analytically pure **5a** as a pale orange solid (31 mg, 15%).^{4a} 1-(4-Chlorophenyl)-2-[(2-nitrophenyl)amino]ethanone (Table **3**, Entry **2**): Yellow solid (266 mg, 91 %); mp = 153-156 °C; ; IR ¹⁰⁵ (KBr) $V_{\text{max}} = 2981, 1275, 1260, 1054, 1033, 764, 750 \text{ cm}^{-1}; {}^{1}\text{H}$ NMR (CDCl₃, 400MHz, TMS) δ: 8.87 (bs, 1H), 8.24 (dd, J=1.52,

www.rsc.org/xxxxxxx | XXXXXXXXX

8.52Hz, 1H), 7.99 (dd, J=1.84, 6.8Hz, 2H), 7.53-7.46 (m, 3H), 6.81-6.72 (m, 2H), 4.76 (d, J=4.4Hz, 2H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ : 191.64, 143.86, 140.80, 138.96, 136.24, 129.45, 129.30, 127.17, 116.17, 114.05, 49.43; MS (APCI) m/z: 5 291 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₄H₁₁ClN₂O₃Na⁺ [M+Na⁺], 313.0350; Found 313.0349.

2-[(4-Chloro-2-nitrophenyl)amino]-1-phenylethanone (Table 3, Entry 3): Yellow solid (258 mg, 89 %); mp = 158-160 °C; IR (KBr) V_{max} = 3342, 3005.58, 1691, 1628, 1561.90, 1517, 1402, 10 1351, 1275, 1261,1156, 1070, 808, 764, 750 cm⁻¹,¹H NMR (CDCl₃, 400MHz, TMS) δ : 8.89 (bs, 1H), 8.24 (d, *J*=2.36Hz, 1H), 8.04 (d, *J*=7.52Hz, 2H), 7.67 (t, *J*=7.4Hz, 1H), 7.55 (t, *J*=7.76Hz, 2H), 7.44 (dd, *J*=2.36, 9.04Hz, 1H), 6.79 (d, *J*=9.04Hz, 1H), 4.77 (d, *J*=4.24Hz, 2H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ : 192.30, 142.62, 136.28, 134.38, 134.30, 129.11, 127.92, 126.32, 120.83, 115.54, 49.44; MS (APCI) m/z: 291 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₄H₁₁ClN₂O₃Na⁺ [M+Na⁺], 313.0350; Found 313.0350.

- **2-[(5-Chloro-2-nitrophenyl)amino]-1-phenylethanone** (Table 20 **3, Entry 4**): Yellow solid (262 mg, 90 %); mp = 155-158 °C; IR (KBr) V_{max} = 3362, 2924, 1695, 1623, 1491, 1275, 1259, 1078, 750 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.00 (bs, 1H), 8.20 (d, *J*=9.08Hz, 1H), 8.06 (d, *J*=1.2Hz, 2H), 7.69 (t, *J*=7.44Hz, 1H), 7.57 (t, *J*=8Hz, 2H), 6.84 (d, *J*=1.96Hz, 1H), 6.72 (dd, *J*=2, 25 9.14Hz, 1H), 4.78 (d, *J*=4.28Hz, 2H); ¹³C NMR (CDCl₃,
- 100MHz, TMS) δ : 192.12, 144.41, 142.70, 134.41, 134.23, 130.17, 129.28, 129.11, 128.52, 128.32, 127.96, 116.48, 113.71 49.39; MS (ESI) m/z: 291 (M+H)⁺. HRMS (ESI) m/z calcd for $C_{14}H_{11}CIN_2O_3Na^+$ [M+Na⁺], 313.0350; Found 312.1499.
- ³⁰ **2-[(4-Methyl-2-nitrophenyl)amino]-1-phenylethanone** (Table **3, Entry 5**): Light yellow solid (248 mg, 92 %); mp = 162-164 °C; IR (KBr) $\boldsymbol{v}_{max} = 3362, 2923, 1742, 1692, 1637, 1561, 1528, 1275, 1155, 750 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) <math>\delta$: 8.78 (bs, 1H), 8.06 (d, *J*=7.56Hz, 3H), 7.67 (t, *J*=7.36Hz, 1H), 7.56 (t,
- ³⁵ J=7.56Hz, 2H), 7.33 (d, J=8.52Hz, 1H), 6.75 (d, J=8.6Hz, 1H), 4.78 (d, J=4.28Hz, 2H), 2.31 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 192.91, 142.19, 137.62, 134.52, 134.17, 132.33, 129.03, 127.89, 126.44, 125.59, 114.12, 49.55, 20.01; MS (APCI) m/z: 271 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₅H₁₄N₂O₃Na⁺
 ⁴⁰ [M+Na⁺], 293.0897; Found 293.0785.

1-(4-Methoxyphenyl)-2-[(4-methyl-2-

nitrophenyl)amino]ethanone (**Table 3, Entry 6**): Yellowish orange solid (270 mg, 90 %); mp = 128-130 °C; IR (KBr) v_{max} = 3364, 2912, 1676, 1632, 1600, 1560, 1524, , 1424, 1348, 1262,

- ⁴⁵ 1241, 1181, 764 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ: 8.75 (bs, 1H), 8.01 (s, 2H), 7.99 (d, *J*=1.96Hz, 1H), 7.28 (dd, *J*=2, 14.5Hz, 1H), 6.99 (d, *J*=1.9Hz, 2H), 6.71 (d, *J*=8.6Hz, 1H), 4.68 (d, *J*=4.4Hz, 2H), 3.88 (s, 3H), 2.27 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 191.31, 164.26, 142.30, 137.59, 132.32,
- $_{50}$ 132.20, 127.51, 126.42, 125.42, 114.18, 113.75, 55.61,49.15, 20.00; MS (ESI) m/z: 301 (M+H)^+. HRMS (ESI) m/z calcd for $C_{16}H_{16}N_2O_4Na^+[M+Na^+]$, 323.1008; Found 323.1005.
- **2-(4-Methoxyphenyl)quinoxaline** (Table 8, Entry 2)^{5k}: Light yellow solid (377 mg, 83 %); mp = 97-98 °C; IR (KBr) V_{max} =
- ⁵⁵ 2926, 1606, 1584, 1274, 1252, 1175, 1028, 834, 763 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz, TMS) δ: 9.28 (s, 1H), 8.18-8.07 (m, 4H), 7.76-7.67 (m, 2H), 7.08-7.04 (m, 2H), 3.87 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 161.45, 151.37, 143.04,

142.30, 141.20, 130.14, 129.39, 129.26, 129.07, 129.01, 60 128.95,114.56, 55.41; MS (ESI) m/z: 237 (M+H)⁺.

- **2-(3-Methoxyphenyl)quinoxaline (Table 8, Entry 3)**^{5k}: Light yellowish orange solid (198 mg, 84 %); mp = 87-88 °C; IR (KBr) $V_{\text{max}} = 3434, 2918, 2846, 2225, 1733, 1275, 1260, 1022, 750 \text{ cm}^{-1}$; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.36 (s, 1H), 8.19-8.13
- ⁶⁵ (m, 2H), 7.92 (dd, *J*=1.8,7.64 Hz, 1H), 7.80-7.74 (m, 2H), 7.52-7.48 (m, 1H), 7.22-7.17 (m, 1H), 7.09 (d, *J*=8.24 Hz, 1H), 3.93 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 157.40, 152.23, 147.30, 142.71, 141.06, 131.61, 131.44, 129.76, 129.55, 129.37, 129.07,126.56, 121.54, 111.43, 55.65; MS (ESI) m/z: 237 ⁷⁰ (M+H)⁺.
- **2-(4-Chlorophenyl)quinoxaline** (Table 8, Entry 4)^{4a}: Light orange solid (197 mg, 82 %); mp = 120-122 °C; IR (KBr) V_{max} = 3004, 2325, 1260, 1275, 764, 750 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.31 (s, 1H), 8.19-8.13 (m, 4H), 7.83-7.75 (m,
- ⁷⁵ 2H), 7.57-7.54 (m, 2H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 150.59, 142.87, 142.22, 141.66, 136.59, 135.19, 130.48, 129.79, 129.60, 129.41, 129.17, 128.78; MS (ESI) m/z: 241 (M+H)⁺.
 2-(4-Bromophenyl)quinoxaline (Table 8, Entry 5)^{5k}: Light

brown solid (238 mg, 84 %); mp = 138 °C; ¹H NMR (CDCl₃, 400 80 MHz, TMS) δ : 9.29 (s, 1H), 8.15-8.07 (m, 4H), 7.82-7.74 (m,

- ⁸⁰ MH2, 1M3) *b*. 9.29 (s, 111, 8.15-8.07 (iii, 411), 7.82-7.74 (iii, 2H), 7.71-7.68 (iii, 2H); 13 C NMR (CDCl₃, 100MHz, TMS) δ : 150.66, 142.83, 142.22, 141.68, 135.62, 132.80, 130.37, 131.88, 130.52, 129.84, 129.60,129.18, 129.02, 125.00; MS (ESI) m/z: 284 (M+H)⁺.
- ⁸⁵ **7-Chloro-2-phenylquinoxaline** (**Table 8, Entry 6**)⁵¹: Light orange solid (194 mg, 81 %); mp = 104-106 °C; IR (KBr) V_{max} = 3047, 2922, 2852. 1606, 1539, 1483,1449, 1404, 1314, 1131, 1073,958, 913,834, 758, 686, 666 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ: 9.30 (s, 1H), 8.20-8.14 (m, 3H), 8.04 (d,
- ⁹⁰ *J*=8.92Hz, 1H), 7.68 (dd, *J*=2.16, 8.84Hz, 1H), 7.58-7.55 (m, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 152.48, 143.38, 142.62, 140.07, 136.27, 136.07, 130.56, 130.48, 130.34, 129.21, 128.95, 128.49, 127.84, 127.60; MS (ESI) m/z: 240 (M)⁺.
- ¹⁰⁰ 7.73-7.66 (m, 1H), 7.10 (d, *J*=8.72Hz, 2H), 3.93 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ : 161.77, 143.88, 143.15, 135.97, 131.21, 130.61, 130.29, 130.00, 129.10, 128.99, 128.79, 128.28, 128.03, 114.68, 55.49; MS (APCI) m/z: 271 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₅H₁₁ClN₂ONa⁺ [M+Na⁺], 293.0452; ¹⁰⁵ Found 293.0452.
- **7-Chloro-2-(4-chlorophenyl)quinoxaline** (**Table 8, Entry 8**): Light orange solid (225 mg, 82 %); mp = 180-182 °C; IR (KBr) \boldsymbol{v}_{max} = 2922, 1521, 1275, 1260, 1022, 764, 750 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ: 9.30 (s, 1H), 8.18-8.15 (m, 3H), 8.07 (d, *J*=8.92Hz, 1H), 7.72 (dd, *J*=2.32, 8.92Hz, 1H) 7.58-7.55 (m, 2H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 151.30, 142.92, 142.56, 140.17, 137.01, 136.33, 134.70, 131.53, 130.77, 130.39, 129.48, 128.82, 128.73, 128.45; MS (APCI) m/z: 275 (M+H)⁺. HRMS (ESI) m/z calcd for C₁₄H₈Cl₂N₂Na⁺ [M+Na⁺], 296.9957; ¹¹⁵ Found 297.1305.

2-(4-Bromophenyl)-7-chloroquinoxaline (Table 8, Entry 9)^{5c}:

Published on 09 January 2015. Downloaded by UNIVERSITY OF OTAGO on 12/01/2015 04:43:49.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

Light brown solid (256 mg, 80 %); mp = 144-146 °C; IR (KBr) V_{max} = 2922, 2075, 1633, 1421, 1176, 1075, 957, 880, 835, 775, 711 cm⁻¹; ¹H NMR (CDCl₃, 400 MHz, TMS) δ : 9.28 (s, 1H), 8.13 (d, *J*=2.24Hz, 1H), 8.09-8.04 (m, 3H), 7.72-7.68 (m, 3H); ¹³C 5 NMR (CDCl₃, 100MHz, TMS) δ : 151.40, 142.89, 142.58, 140.21, 136.37, 135.16, 132.46, 130.82, 130.41, 129.06, 128.97,

128.47, 128.13, 125.44; MS (APCI) m/z: 321 (M+2H)⁺.

6-Chloro-2-phenylquinoxaline (**Table 8, Entry 10**)⁵¹: Colorless crystal (199 mg, 83 %); mp = 125-127 °C; IR (KBr) *V*_{max} = 10 3367, 2162, 1276, 1256, 752 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ: 9.34 (s, 1H), 8.21-8.19 (m, 2H), 8.13-8.09 (m, 2H), 7.74 (dd, *J*=2.36, 8.96Hz, 1H), 7.62-7.55 (m, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 151.95, 144.16, 141.82, 140.85, 136.38, 135.26, 131.34, 130.85, 130.45, 129.24, 128.09, 127.53; MS ¹⁵ (APCI) m/z: 241 (M+H)⁺.

6-Chloro-2-(4-methoxyphenyl)quinoxaline (**Table 8, Entry 11**)⁵¹.Off-white solid (219 mg, 81 %); mp = 140-142 °C; IR (KBr) \mathcal{V}_{max} = 2930, 2837, 1674, 1606, 1577, 1538, 1519, 1454, 1309, 1287, 1273, 1257, 1171, 1066, 1026, 957, 827, 764, 750, 20 570, 515 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.29 (s, 1H), 8.18 (dd, *J*=1.84, 7Hz, 2H), 8.09 (d, *J*=2.2Hz, 1H), 8.05 (d, *J*=8.96Hz, 1H), 7.71 (dd, *J*=2.28, 8.92Hz, 1H), 7.09 (dd, *J*=1.76, 6.92Hz, 2H), 3.92 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ :

161.68, 151.53, 143.84, 141.42, 140.87, 134.66, 131.18, 130.60, ²⁵ 128.97, 128.86, 128.02, 114.67, 55.46; MS (APCI) m/z: 271 (M+H)⁺. HRMS (ESI) m/z calcd for $C_{15}H_{11}CIN_2ONa^+$ [M+Na⁺], 293.0452; Found 293.0451.

6-Chloro-2-(4-chlorophenyl)quinoxaline (**Table 8, Entry 12**): Yellowish orange solid (225 mg, 82 %); mp = 130-132 °C; IR

- ³⁰ (KBr) $\mathcal{W}_{max} = 2917, 2849, 1275, 1260, 750 \text{ cm}^{-1}; {}^{1}\text{H}$ NMR (CDCl₃, 400MHz, TMS) δ : 9.32 (s, 1H), 8.17 (dd, *J*=1.92, 6.72Hz, 2H), 8.14 (d, *J*=2.28Hz, 1H), 8.09 (d, *J*=8.96Hz, 1H), 7.76 (dd, *J*=2.28, 8.96Hz, 1H), 7.57 (dd, *J*=1.96, 6.68Hz, 2H); {}^{13}\text{C} NMR (CDCl₃, 100MHz, TMS) δ : 150.70, 143.67,141.88, 140.76 (120.20, 120.69, 125.55, 124.77, 121.55, 120.92, 120.69, 125.55, 124.77, 121.55, 120.92, 120.69, 125.55, 124.77, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.69, 125.55, 124.75, 121.55, 120.92, 120.55, 120.75, 120.55, 120.75, 120.55, 120.75, 120.55, 120.75, 120.55, 120.55, 120.75, 120.55, 120.75, 120.55
- 35 140.76, 139.29, 136.88, 135.55, 134.77, 131.55, 130.80, 129.49, 128.73, 128.12, 114.07; MS (APCI) m/z: 275 $(M+H)^+$. HRMS (ESI) m/z calcd for $C_{14}H_8Cl_2N_2Na^+$ [M+Na^+], 296.9957; Found 297.1298.
- **2-(4-Bromophenyl)-6-chloroquinoxaline (Table 8, Entry 13)**: ⁴⁰ Off-white solid (257 mg, 83 %); mp = 175-177 °C; IR (KBr) V_{max} = 3049, 2923, 2849, 1604, 1539, 1476, 1328, 1275, 1176, 1004, 919, 825, 750, 569 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.27 (s, 1H), 8.09 (d, *J*=2.24Hz, 1H), 8.06 (d, *J*=8.48Hz, 3H), 7.73-7.67 (m, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ : 150.74,
- $_{45}$ 143.61, 141.90, 140.76, 135.58, 135.20, 132.45, 131.56, 130.81, 130.40, 129.04, 128.95, 128.12, 125.29; MS (APCI) m/z: 321 (M+H)^+. HRMS (ESI) m/z calcd for $C_{14}H_8BrClN_2Na^+$ [M+Na^+], 340.9452; Found 341.1820.
- **2-(4-Methoxyphenyl)-7-methylquinoxaline** (Table 8, Entry ⁵⁰ 14)^{4e}: Light yellow solid (200 mg, 80 %); mp = 52-57 °C; IR (KBr) $\mathbf{v}_{max} = 2917, 2857, 2307, 1956, 1739, 1618, 1451, 1384, 1179, 1050, 746 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) <math>\delta$: 9.26 (s, 1H), 8.19-8.16 (m, 2H), 8.01 (dd, *J*=8.52,12.32 Hz, 1H), 7.97

ARTICLE TYPE

- (d, *J*=14.28Hz 1H), 7.62- 7.55 (m, 1H), 7.10 (d, *J*=8.44Hz 2H), 55 3.92 (s, 3H), 2.62 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 161.30, 142.99, 142.19, 139.57, 132.48, 131.37, 129.51, 128.92, 128.82, 128.58, 128.29, 127.97, 114.56, 55.45, 21.80; MS (ESI) m/z: 251 (M+H)⁺.
- **2-(4-Bromophenyl)-7-methylquinoxaline** (Table 8, Entry ⁶⁰ **15**)^{5c}: Yellowish orange (238 mg, 80 %); mp = 96-98 °C; IR (KBr) \mathcal{W}_{max} = 2920, 2851, 1624, 1587, 1488, 1436, 1131, 1072, 1009, 960, 834, 777 cm⁻¹; ¹H NMR (CDCl₃, 400MHz, TMS) δ : 9.22 (s, 1H), 8.06 (dd, *J*=1.92, 6.64Hz, 2H), 7.99 (d, *J*=8.56Hz, 1H), 7.91 (s, 1H), 7.68 (dd, *J*=1.84, 6.72Hz, 2H), 7.58 (dd,
- ⁶⁵ *J*=1.84, 8.56Hz, 1H), 2.61 (s, 3H); ¹³C NMR (CDCl₃, 100MHz, TMS) δ: 150.58, 142.31, 141.92, 141.11, 140.21, 135.82, 132.32, 132.18, 128.97, 128.89, 128.66, 128.43, 124.83, 21.91; MS (APCI) m/z: 299 (M+H)⁺. HRMS (ESI) m/z calcd for $C_{15}H_{11}BrN_2Na^+$ [M+H⁺], 299.0106; Found 299.0178.
- ⁷⁰ **7-Methoxy-2-phenylquinoxaline** (**Table 8, Entry 16**)⁵ⁱ:Colorless crystal (193 mg, 82 %); mp = 86-88 °C; IR (KBr) $\boldsymbol{V}_{max} = 2917, 2840, 1733, 1459, 1260, 1078, 1025, 750 cm⁻¹; ¹H$ NMR (CDCl₃, 400MHz, TMS) δ: 9.19 (s, 1H), 8.20-8.18 (m,2H), 8.02 (d,*J*=9.12Hz, 1H), 7.61-7.54 (m, 3H), 7.45 (d,75*J*=2.72Hz, 1H), 7.42 (dd,*J*=2.76, 9.12Hz, 1H), 4.02 (s, 3H); ¹³CNMR (CDCl₃, 100MHz, TMS) δ: 161.09, 151.98, 143.99,140.79, 137.81, 137.03, 130.06, 129.14, 127.53, 122.92, 106.90,55.86; MS (ESI) m/z: 237 (M+H)⁺.

Acknowledgement

⁸⁰ Financial support from UGC (SRF to BT) and CSIR (RA to DK), New Delhi is thankfully acknowledged.

Notes and references

^aDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. 85 Nagar 160 062, Punjab, India. E-mail: akchakraborti@niper.ac.in

† Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/b000000x/

- 90 (1) (a) A. Cartra, P. Corona and M. Loriga, *Curr. Med. Chem.* 2005, 12, 2259; (b) A. Cartra, S. Piras, G. Loriga and G. Paglietti, *Mini Rev. Med. Chem.* 2006, 6, 1179; (c) R. M. Rajurkar, V. A. Agrawal, S. S. Thonte and R. G. Ingale, *Pharmacophore* 2010, 1, 65; (d) M. González and H. Cerecetto, *Expert Opin. Ther. Pat.* 2012, 22, 1289; (e) R. G. Ingle and R. P. Marathe, *Pharmacophore* 2012, 3, 109.
- (2) Vareniciline (a) S. D. Shah, L. A. Wilken, S. R. Winkler and S. J. Lin, *J. Am. Pharm. Assoc.* (2003), 2008, 48, 659; Carbadox (b) B. Emmert, S. Schauder, H. Palm, E. Hallier and S. Emmert, Ann. *Agric. Environ. Med.* 2007, 14, 329; Brimonidine (c) C. B. Toris, C. B. Camras and M. Yablonski, *E. Am. J. Opthal.* 1999, 128, 8.
- (3) Fluorescent dyes (a) N. D. Sonawane and D. W. Rangnekar, J. *Heterocycl. Chem.* 2002, 39, 303; Electroluminescence (b) C. T. Chen, J. S. Lin, M. V. R. K. Moturu, Y. W. Lin, W. Yi, Y. T. Tao and C. H. Chien, *Chem. Commun.* 2005, 3980; Semiconductor (c) S. Dailey, J. W. Feast, R. J. Peace, I. C. Sage, S. Till and E. L. Wood, *J. Mater. Chem.* 2001, 11, 2238; Chemically controllable switches (d) S. Ott aand R. Faust, *Synlett* 2004, 1509; Electron transport

Page 10 of 11

materials (e) D. O'Brien, M. S. Weaver, D. G. Lidzey and D. D. C. Bradley, *Appl. Phys. Lett.* 1996, **69**, 881.

- (4) (a) S. B. Wadavrao, R. S. Ghogare and A. V. Narsaiah, Org. Commun. 2013, 6, 23; (b) Y. Chen, K. Li, M. Zhao, Y. Li and B. Chen, Tetrahedron Lett. 2013, 54, 1627; (c) M. J. Climent, A. Corma, J. C. Hernández, A. B. Hungría, S. borra and S. I Martínez-Silvestre, J. Catal. 2012, 292, 118; (d) P. Ghosh and A. Mandal, Tetrahedron Lett. 2012, 53, 6483; (e) L. Nagarapu, R. Mallepalli, G. Arava and L. Yeramanchi, Eur. J. Chem. 2010, 1, 228; (f) B.
- Madhav, S. Narayan Murthy, V. Prakash Reddy, K. Rama Rao and Y. V. D. Nageswar, *Tetrahedron Lett.* 2009, **50**, 6025; (g) J.-P. Wan, S.-F. Gan, J.-M. Wu and Y. Pan, *Green Chem.* 2009, **11**, 1633; (h) T. Huang, Q. Zhang, J. Chen, W. Gao, J. Ding and H. Wu, *J. Chem. Res.* 2009, 761. (i) D. Chang-jiang, W. Yan, Z. Wei-wei,
- L. Li, L. Yong-jiu and D. De-wen, *Chem. Res. Chin. Univ* 2009, 25, 174; (j) B. Das, K. Venkateswarlu, K. Suneel and A. Majhi, *Tetrahedron Lett.* 2007, 48, 5371; Reviews (k) V. A. Mamedov and N. A. Zhukova, *Prog. Heterocycl. Chem.* 2012, 24, 55; (l) V. A. Mamedov and N. A. Zhukova, *Prog. Heterocycl. Chem.* 2013, 25, 1; (m) Y. V. D. Nageswar, K. H. V. Reddy, K. Ramesh and S. N. Murthy, *Org. Prep. Proced. Int.* 2013, 45, 1.
- (5) (a) S. A. Raw, C. D. Wilfred and R. J. K. Taylor, Org. Biomol. Chem. 2004, 2, 788; (b) C. Neochoritis, J. Stephanidou-Stephanatou and C. A. Tsoleridis, Synlett, 2009, 302; (c) H. M. Meshram, G. S. kumar, P. Ramesh and B. C. Reddy, Tetrahedron Lett. 2010, 51, 2580; (d) S. Paul and B. Basu, Tetrahedron Lett. 2011, 52, 6597; (e)
- L. J. Martin, A. L. Marzinzik, S. V. Ley and I. R. Baxendale, Org. Lett. 2011, 13, 320; (f) W. Wang, Y. Shen, M. Zhao, Y. Chen and B. Chen, Org. Lett. 2011, 13, 4514; (g) F. Pan, T. -M. Chen, J.-J.
 Chen, Org. Lett. 2011, 13, 4514; (g) F. Pan, T. -M. Chen, J.-J.
- Cao, J.-P. Zhou and W. Zhang, *Tetrahedron Lett.* 2012, 53, 2508;
 (h) C. Zhang, Z. Xu, L. Zhang and N. Jiao, *Tetrahedron* 2012, 68, 5258;
 (i) J. Song, X. Li, Y. Chen, M. Zhao, Y. Dou and B. Chen, *Synlett* 2012, 2416;
 (j) M. Lian, Q. Li, Y. Zhu, G. Yin and A. Wu, *Tetrahedron* 2012, 68, 9598;
 (k) T. B. Nguyen, P. Retailleau and A. Maynetti, *Curr. Lett.* 2012, 15, 5228;
- Al-Mourabit, Org. Lett. 2013, 15, 5238; (I) K. Aghapoor, F. Mohsenzadeh, A. Shakeri, H. R. Darabi, M. Ghassemzadeh and B. Neumüller J. Organomet. Chem. 2013, 743, 170.
- (6) J. Machin and D. M. Smith, J. Chem. Soc., Perkin Trans. 1 1979, 1371.
- 40 (7) (a) V. Sridharan, S. Perumal, C. Avendaño and J. C. Menéndez, Synlett 2006, 91; (b) Y. Vara, E. Aldaba, A. Arrieta, J. L. Pizarro, M. L. Arriortua and F. P. Cossío, Org. Biomol. Chem. 2008, 6, 1763.
- (8) I. Vilotijevic and T. F. Jamison, Science 2007, 317, 1189.
- ⁴⁵ (9) (a) A. Shokri, J. Schmidt, X.-B. Wang and S. R. Kass, *J. Am. Chem. Soc.* 2012, **134**, 2094; (b) A. Shokri, A. Abedin, A. Fattahi and S. R. Kass, *J. Am. Chem. Soc.* 2012, **134**, 10646.
- (10) Organic reactions promoted through HB formation with water: (a)
 S. V. Chankeshwara and A. K. Chakraborti, *Org. Lett.* 2006, *8*,
- 3259; (b) G. L. Khatik, R. Kumar and A. K. Chakraborti, *Org. Lett.* 2006, **8**, 2433; (c) A. K. Chakraborti, S. Rudrawar, K. B. Jadhav, G. Kaur and S. V. Chankeshwara, *Green Chem.* 2007, **9**, 1335; (d) N. Parikh, D. Kumar, S. Raha Roy and A. K. Chakraborti, *J. Chem. Soc. Chem. Commun.* 2011, **47**, 1797; (e) D. N. Kommi, D. Kumar,
- R. Bansal, R. Chebolu and A. K. Chakraborti, *Green Chem.* 2012, 14, 3329; (f) D. N. Kommi, P. S. Jadhavar, D. Kumar and A. K. Chakraborti, *Green Chem.* 2013, 15, 798; (g) D. N. Kommi, D. Kumar and A. K. Chakraborti, *Green Chem.* 2013, 15, 756; (h) D. N. Kommi, D. Kumar, K. Seth and A. K. Chakraborti, *Org. Lett.*
- 60 2013, **15**, 1158. (i) D. Kumar, K. Seth, D. N. Kommi, S. Bhagat and A. K. Chakraborti, *RSC Advances* 2013, **3**, 15157; (j) K. Seth, S. Raha Roy, B. V. Pipaliya and A. K. Chakraborti, *J. Chem. Soc. Chem. Commun.* 2013, **49**, 5886.
- (11) (a) D. Kumar, D. N. Kommi, A. R. Patel and A. K. Chakraborti, *Eur J. Org. Chem.* 2012, 6407; (b) A. Sarkar, S. Raha Roy, D. Kumar, C. Madaan, S. Rudrawar and A. K. Chakraborti, *Org. Biomol. Chem.* 2012, **10**, 281; (c) A. Sarkar, S. Raha Roy, N. Parikh and A. K. Chakraborti, *J. Org. Chem.* 2011, **76**, 7132; (d) S. Raha Roy, P. S. Jadhavar, K. Seth, K. K. Sharma and A. K. Chakraborti, *Synthesis*
- ⁷⁰ 2011, 2261; (e) A. Sarkar, S. Raha Roy and A. K. Chakraborti, J. Chem. Soc. Chem. Commun. 2011, **47**, 4538; (f) S. Raha Roy and A. K. Chakraborti, Org. Lett. 2010, **12**, 3866; (g) A. K. Chakraborti and S. Raha Roy, J. Am. Chem. Soc. 2009, **131**, 6902; (h) A. K.

Chakraborti, S. Raha Roy, D. Kumar and Pradeep Chopra, *Green Chem.* 2008, **10**, 1111.

- (12) (a) A. K. Chakraborti, S. Rudrawar, L. Sharma and G. Kaur, *Synlett* 2004, 1533; (b) A. K. Chakraborti, L. Sharma and M. K. Nayak, *J. Org. Chem.* 2002, **67**, 6406; (c) A. K. Chakraborti, M. K. Nayak and L. Sharma, *J. Org. Chem.* 1999, **64**, 8027; (d) L. Sharma, M. K.
 Nayak and A. K. Chakraborti, *Tetrahedron* 1999, **55**, 9595; (e) M. K. Nayak and A. K. Chakraborti, *Tetrahedron Lett.* 1997, **38**, 8749.
- (13) (a) R. Chebolu, D. N. Kommi, D. Kumar, N. Bollineni and A. K. Chakraborti, *J. Org. Chem.* 2012, **77**, 10158; (b) A. K. Chakraborti, L. Sharma and M. K. Nayak, *J. Org. Chem.* 2002, **67**, 2541; (c) M. K. Nayak and A. K. Chakraborti, *Chem. Lett.* 1998, **27**, 297.
- (14) M. J. Kamlet, J. M. Abboud, M. H. Abraham and R. W. Taft, J. Org. Chem. 1983, 48, 2877.
- (15) J. G. Lee, K. I. Choi, H. Y. Koh, Y. Kim, Y. Kang and Y. S. Cho, *Synthesis* 2001, 81.
- 90 (16) N. G. Connelly and W. E. Geiger, Chem. Rev. 1996, 96, 877.
- (17) (a) E. Lellmann and A. Donner, *Chem. Ber.* 1890, 23, 166; (b) D. C. Blaildey, D. W. Currie, D. M. Smith and S. A. Watson, *J. Chem. Soc. Perkin Trans. I* 1984, 367.
- (18) (a) F. Jahani, M. Tajbakhsh, H. Golchoubian and S. Khaksar, *Tetrahedron Lett.* 2011, **52**, 1260; (b) A. Heydari and S. E. Hosseini, *Adv. Synth. Catal.* 2005, **347**, 1929; (c) L. Xi, J.-Q Z.-C. Liu, J.-H. Zhang, J.-F. Yan, Y. Jin and J. Lin, *Org. Biomol. Chem.* 2013, **11**, 4367; (d) R. Varala, S. Nuvula and R. Srinivas *J. Org. Chem.* 2006, **71**, 8283; (e) D. A. Stolfa, A. Stefanachi, J. M. Gajer, A. Nebbioso, L. Altucci, S. Cellamare, M. Jung and A. Carotti, *Chem. Med. Chem.* 2012, **7**, 1256.
- (19) J. Wang, Y. L. Liang and J. Qu, Chem. Commun. 2009, 5144.
- (20) J. Choy, S. Jaime-Figueroa, L. Jiang and P. Wagner, Synth. Commun. 2008, 38, 3840.


Graphical Abstract

An "all-water" strategy for regiocontrolled synthesis of 2-aryl quinoxalines

Babita Tanwar, Priyank Purohit, Banothu Naga Raju, Dinesh Kumar, Damodara N. Kommi and Asit K. Chakraborti *

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar 160 062, Punjab, India.

E. mail: akchakraborti@niper.ac.in; akchakraborti@rediffmail.com



Cascade *N*-aroylmethylation–reduction–condensation process as novel strategy of "all water chemistry" for first generalized regioselective synthesis of 2-aryl quinoxalines.